RSC Advances

ROYAL SOCIETY OF CHEMISTRY

www.rsc.org/advances

Journal Name

Dynamic Article Links ►

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE

Total Synthesis of Phenanthroindolizidine Alkaloids via Asymmetric Deprotonation of *N*-Boc-pyrrolidine

Meng Deng,[a] Bo Su,[a] Hui Zhang,[a] Yuxiu Liu, [a] and Qingmin Wang * [a]

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX

DOI: 10.1039/b000000x

A concise and efficient enantioselective strategy to two typical phenanthroindolizidine alkaloids 14-hydroxyantofine and antofine was developed, featuring an asymmetric deprotonation/diastereoselective carbonyl addition sequence, during which the formation of chiral C-13a center and connection of pyrrolidine and phenanthrene moieties were achieved efficiently in one step. The absolute configuration of C-13a stereocenter can be delicately controlled by using different enantiomers of sparteine, both of which are commercially available.

Introduction

Phenanthroindolizidine alkaloids, isolated mainly from *Tylophora, Cynanchun, Pergularia,* and some genera of the *Asclepiadaceas* family, have attracted continuous attention from both synthetic and pharmaceutical community owing to their unique structural features and low natural abundance, as well as noteworthy biological activities since the first isolation of (*R*)-tylophorine [(–)-**1b**] (Figure 1) in 1935.[1]

In the past decades, a number of impressive enantioselective synthetic routes to phenanthroindolizidine alkaloids have been reported.[1c, 2] As these alkaloids possess a stereogenic center at the α position of the nitrogen atom, the chiron approach starting with optical α-amino acids or their derivatives have been widely used.[1c, 2b, d, e, h, i, k] Except that, a few other remarkable strategies have also been employed in recent years, including the chiral auxiliary procedure,[2j, 3] asymmetric transition-metal-catalyzed intramolecular carboamination,[2c, f] enantioselective phase-transfer alkylation,[2a] and proline-catalyzed asymmetric α-aminoxylation of aldehyde,[2g] etc. Although a sustainable source of these alkaloids for bioactivity studies can be provided by approaches mentioned above, more efficient synthetic strategy is still desirable.



R^1 = H, (+)-antofine (**1a**)
R^1 = OMe, (+)-tylophorine (**1b**)



(+)-14-hydroxyantofine (**2**)



(+)-sparteine (**L**)

Figure 1. Representative phenanthroindolizidine alkaloids and (+)-sparteine (**L**).

Asymmetric deprotonation of *N*-Boc-pyrrolidine by *s*-BuLi/(+)-sparteine, which gave a configurationally preferred carbanion, followed by nucleophilic substitution/ addition was an attractive approach developed by Beak et al for the direct functionalizaion of pyrrolidine (Scheme 1).[4] Although detailed

[a] *State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, Nankai University, Collaborative Innovation Center of Chemical Science and Engineering(Tianjin), Tianjin 300071, People's Republic of China. E-mail: wang98h@263.net; wangqm@nankai.edu.cn.*

mechanism studies have been done for this elegant and creative methodology,[5] only a few successful applications in total synthesis of natural products and chiral drug molecules were reported, most of which used sinuous approaches to realize the asymmetric functionalization.[4d–e, 6] To showcase the efficiency and convenience of this methodology, we wish herein to report a concise synthesis of (+)-14-hydroxyantofine (**2**) and (+)-antofine (**1a**), both of which are enantiomers of these alkaloids in nature (Figure 1).



Scheme 1. Asymmetric deprotonation of *N*-Boc-pyrrolidine by *s*-BuLi/(+)-sparteine (**L**).

Results and Discussion

Retrosynthetically, (+)-Antofine (**1a**) and (+)-14-hydroxyantofine (**2**) were envisioned to be accessible via Pictet–Spengler cyclization from compounds **5** (Table 1) and **7a/7b** (Scheme 3), respectively. Key intermediate **5** could be obtained by a S_N2 substitution of chiral 2-lithio-*N*-Boc-pyrrolidine (**3**) to **4a** or **4b** (Table 1), and **7a/7b** by a nucleophilic carbonyl addition of **3** to phenanthryl aldehyde **6** (Table 1). The starting materials **4a**,[7a] **4b**[2i] and **6**[7b] were readily available by using an efficient and practical $FeCl_3$-mediated oxidative coupling method for constructing polymethoxy-phenanthrene moiety developed by our group.[8]

Initially, alkylation of *N*-Boc-pyrrolidine with bromide **4b** was put into practice, as was shown in Table 1. To explore the reactivity, tetramethylethylenediamine (TMEDA) was first employed as ligand. Deprotonation of *N*-Boc-pyrrolidine with *s*-BuLi/TMEDA gave (±)-2-lithio-*N*-Boc-pyrrolidine, then bromide **4b** was added. Gratifyingly, the desired coupled product (±)-**5** was obtained in moderate yield. It is worth to note that a main by-product **5a** was isolated in 22% yield, which was believed to be produced from lithium–bromide exchange[9] of **4b** with 2-lithio-*N*-Boc-pyrrolidine and subsequent dimerization. To decrease the lithium–halogen exchange, **4b** was replaced by chloride **4a**, which showed that **4a** could give better result (Table 1, entry 1).

After investigating the reactivity of *N*-Boc-pyrrolidine, asymmetric version was effected by using chiral ligand (+)-sparteine (Table 1, entries 3 and 4). Although great effort was paid on optimizing the reaction conditions, unfortunately, the desired product **5** could only be obtained in moderate enantiomeric excess and low yield. The lower yield was proposed due to the steric effect when relatively bulky ligand was introduced. The subsequent Pictet-Spengler cyclization proved to be effective, giving antofine (**1a**) in high yield (91%) and moderate ee (60%).

It was thought that the notable lithium–halogen exchange[9] during the alkylation should be responsible for the unsatisfying yield and ee. To explore the mechanism, 2,2,6,6-Tetramethylpiperidine 1-oxyl (TEMPO) was introduced into the reaction system (Table 1, entry 5).[10] Product **5** was gained in reduced yield (23%) but slightly raised ee (58%). Meanwhile, a radical trapping product **4c** (Table 1) was isolated in 18% yield, which suggested a free radical process, as shown in Scheme 2. Besides generated by direct S_N2 substitution of chiral **3** with **4b**, **5** could also be produced by a free radical coupling after the single electron transfer (SET) process between **3** and **4b**, during which the racemization of chiral **3** and dimerization of free radical intermediate **4r** was unavoidable. We declared that this SET mechanism is at least a minor pathway but there must exists a lithium–halogen exchange pathway not involving SET.[9, 11]



Entry	Ligand	Electrophiles	Yield (%)[a]		ee%
			5	**5a**	
1	TMEDA	**4a**	62	16	--
2	TMEDA	**4b**	50	22	--
3	(+)-sparteine	**4a**	33	11	62
4	(+)-sparteine	**4b**	37	17	53
5[b]	(+)-sparteine	**4b**	23	12	58

General reaction conditions: see procedure **A** and **B** in experimental section. a) Isolated yield; b) 2.0 equiv. TEMPO was added along with **4b**, and product **4c** was isolated in 18% yield .



X = -CH_2Cl, **4a**
X = -CH_2Br, **4b**



X = -CHO, **6**

Table 1. Synthesis of (+)-antofine (**1a**) by alkylation of *N*-Boc-pyrrolidine.



Scheme 2. Proposed mechanism of lithium–halogen exchange between **3** and **4b**.

To avoid lithium–halogen exchange, the second strategy—carbonyl addition of **3** to **6**—was explored (Scheme 3). To our delight, treatment of *N*-Boc-pyrrolidine with *s*-BuLi/(+)-sparteine in diethyl ether gave chiral **3**, which underwent reaction with phenanthryl aldehyde **6** to give the enantiomerically enriched, diastereomeric intermediates **7a** and **7b** in 26% and 61% yield, respectively. Then diastereoisomers **7a** and **7b** were subjected to Pictet–Spengler cyclization conditions separately. Interestingly, both isomers gave the same cyclization product **2** in moderate yields (58%, 54%) and high

ee (97%, 96%), and the other diastereomeric product was not detected. It was believed that racemization at the C-14 stereocenter occurred under the harsh acidic Pictet–Spengler cyclization conditions, so only one configurationally preferred product was obtained. The NMR data of synthesized product **2** were identical to those reported in literature.[12] However, the specific rotation of compound **2** was opposite with natural product, thus we confirmed that the absolute configuration of **2** was (13a*S*, 14*S*). After dehydroxylation, **1a** was obtained in 96% yield and 98% ee.



Scheme 3. Synthesis of (+)-14-hydroxyantofine (**2**) and (+)-antofine (**1a**) by carbonyl addition of *N*-Boc-pyrrolidine.

Conclusions

In conclusion, a concise strategy to two typical phenanthroindolizidine alkaloids antofine (**1a**) and 14-hydroxyantofine (**2**) has been explored, featuring an asymmetric deprotonation of the *N*-Boc-pyrrolidine followed by reacting with carbon electrophiles. For the alkylation of compounds **3** with **4**, a notable lithium–halogen exchange was observed, which should account for the unsatisfying yield and ee. For the carbonyl addition of **3** to **6**, a gratifying result was obtained. Product **2** was gained in 47% total yield and 96–97% ee from **6** in two steps, then undergoing one more step **1a** could be obtained in 96% yield and 98% ee.

Experimental Section

General Information. The melting points were determined with an X-4 binocular microscope melting-point apparatus and were uncorrected. ^{1}H NMR spectra were obtained by using Bruker AV 400 spectrometer. Chemical shifts (δ) were given in parts per million (ppm) and were measured downfield from internal tetramethylsilane. ^{13}C NMR spectra were recorded by using a Bruker AV 400 instrument (100 MHz) and $CDCl_3$ as solvent. Chemical shifts (δ) were reported in parts per million. High-resolution mass spectra were obtained with an FT-ICR MS spectrometer (Ionspec, 7.0 T). Optical rotations were measured with Autopol IV auto digital polarimeter (Rudolph Research Analytical). All anhydrous solvents were dried and purified by standard techniques just before use. All reagents were purchased from commercial suppliers without further purification. Reactions were monitored by thin layer chromatography on plates (GF254) using UV light as visualizing agent. (+)-Sparteine was purchased from Aladdin Industrial Corporation. If not noted otherwise, flash column chromatography used silica gel (200−300 mesh).

Procedure A: racemic deprotonation of *N*-Boc-pyrrolidine and subsequent functionalization (Table 1, entry 1-2). To a solution of TMEDA (278 mg, 2.4 mmol, 1.2 equiv) and *N*-Boc-pyrrolidine (344 mg, 2.0 mmol, 1.0 equiv) in Et_2O (60 mL) at –78 °C was added *s*-BuLi (2.2 mL, 1.0 M in hexane, 1.1 equiv). The reaction mixture was stirred for 4 h at –78 °C, and then a suspension of electrophile **4** or **6** (1.0 mmol, 0.5 equiv) in Et_2O(10 mL) was added. The mixture was stirred for 4–6 h at –78 °C, then allowed to warm slowly to 0 °C in 3 h. Workup consisted of addition of water (20 mL), extraction of the aqueous layer with Et_2O (2 × 10 mL), extraction of the combined Et_2O extracts with 5%

phosphoric acid (2 × 10 mL) and brine (2 × 10 mL), drying over anhydrous magnesium sulfate, filtration, and concentration in vacuo.

Procedure B: asymmetric deprotonation of *N*-Boc-pyrrolidine and subsequent functionalization (Table 1, entry 3-5). To a solution of (+)-sparteine (563 mg, 2.4 mmol, 1.2 equiv) and *N*-Boc-pyrrolidine (344 mg, 2.0 mmol, 1.0 equiv) in Et_2O (60 mL) at –78 °C was added *s*-BuLi (2.2 mL, 1.0 M in hexane, 1.1 equiv). The following operation was in accordance with procedure **A**.

Preparation of Racemic 5 and 5a From 4a or 4b (Table 1, entry 1-2). Took **4a** for example (Table 1, entry 1), lithiation of *N*-Boc-pyrrolidine according to procedure **A**, then a suspension of **4a** (317 mg, 1.0 mmol) in Et_2O (10 mL) was added. Purification by flash chromatography with 1/6 (v/v) EtOAc/hexane, followed by recrystallizing from 1.0 mL methanol gave racemic **5** (280 mg, 62%) as a white solid; m.p. 150–152 °C (ref.[2b] 99–101 °C). ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.33 (s, 1 H, Ar-H), 7.91 (s, 1 H, Ar-H), 7.85 (d, J = 2.0 Hz, 1 H, Ar-H), 7.73 (d, J = 8.8 Hz, 1 H, Ar-H), 7.39 (s, 1 H, Ar-H), 7.17 (dd, J = 8.8, 2.0 Hz, 1 H, Ar-H), 4.26 (m, 1 H, N-CH, 2-H), 4.22 (s, 3 H, OMe), 4.12 (s, 3 H, OMe), 4.02 (s, 3 H, OMe), 3.92 (m, 1 H, Ar-CH_2), 3.49 (m, 1 H, Ar-CH_2), 3.32 (m, 1 H, N-CH_2, 5-H), 2.59 (m, 1 H, N-CH_2, 5-H), 2.02 (m, 1 H, 3-H), 1.84 (m, 2 H, 3-H, 4-H), 1.67 (m, 1 H, 4-H), 1.51 (s, 9 H, CH_3) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.8, 154.7, 149.8, 148.7, 131.1, 130.6, 129.5, 127.3, 126.0, 125.7, 124.5, 115.2, 106.8, 103.9, 103.4, 78.9, 57.2, 56.7, 56.0, 55.6, 46.8, 38.6, 29.0, 28.6, 23.5 ppm. Filtering the insoluble solid out of the organic/aqueous phase during the workup procedure gave **5a** (45 mg, 16%) as an off-white solid; m.p. 265–270 °C. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.95 (s, 2 H, Ar-H), 7.87 (d, J = 2.4 Hz, 2 H, Ar-H), 7.74 (d, J = 8.8 Hz, 2 H, Ar-H), 7.58 (s, 2 H, Ar-H), 7.37 (s, 2 H, Ar-H), 7.20 (dd, J = 8.7, 2.4 Hz, 2 H, Ar-H), 4.12 (s, 6 H, OMe), 4.04 (s, 6 H, OMe), 3.87 (s, 6 H, OMe), 3.57 (s, 4 H, Ar-CH_2) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.9, 149.3, 148.7, 133.1, 130.3, 129.6, 126.8, 126.2, 124.8, 124.1, 115.5, 104.7, 104.7, 103.9, 56.0, 55.8, 55.6, 33.8 ppm. HRMS (ESI): calcd. for $C_{36}H_{35}O_6$ $[M+H]^+$ 563.2428, found 563.2423.

Preparation of (+)-5 and 5a From 4a or 4b (Table 1, entry 3-4). Took **4a** for example (Table 1, entry 4), lithiation of *N*-Boc-pyrrolidine according to procedure **B**, then a suspension of **4a** (317 mg, 1.0 mmol) in Et_2O (10 mL) was added. Purification by flash chromatography with 1/6 (v/v) EtOAc/hexane, followed by recrystallizing from 1.0 mL methanol gave (+)-**5** (150 mg, 33%) as a white solid. Chiral HPLC analysis (Chiralcel AD-H column, i-PrOH : hexane = 10:90, 1.0 mL/ min) showed that the product had an enantiomeric excess of 62%. Filtering the insoluble solid out of the organic/aqueous phase during the workup procedure gave **5a** (31 mg, 11%) as an off-white solid. Other data were the same as those of racemic **5** and **5a** in procedure **A**.

Preparation of (+)-5, 4c, and 5a From 4b (Table 1, entry 5). Lithiation of *N*-Boc-pyrrolidine according to procedure **B**, then a suspension of **4b** (361 mg, 1.0 mmol, 0.5 equiv) and TEMPO (624 mg, 4.0 mmol, 2.0 equiv) in Et_2O（10 mL） was added. Purification by flash chromatography with 1/10 (v/v) EtOAc/hexane gave (+)-**5** (106 mg, 23%) as a white solid [Chiral HPLC analysis (Chiralcel AD-H column, i-PrOH : hexane = 10:90, 1.0 mL/ min) showed that the product had an enantiomeric excess of 58%]; and **4c** (80mg, 18%) as a white soild; m.p. 138–139 °C. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.93 (s, 1H, Ar-H), 7.86 (d, J = 2.4 Hz, 1H, Ar-H), 7.81 (d, J = 8.8 Hz, 1H, Ar-H), 7.66 (s, 1H, Ar-H), 7.50 (s, 1H, Ar-H), 7.20 (dd, J = 8.8, 2.4 Hz, 1H, Ar-H), 5.24 (s, 2H, Ar-CH_2), 4.12 (s, 3H, OMe), 4.07 (s, 3H, OMe), 4.03 (s, 3H, OMe), 1.59–1.52 (m, 6H, CH_2), 1.37 (s, 6H, CH_3), 1.18 (s, 6H, CH_3) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.3, 149.3, 148.7, 131.0, 130.3, 129.2, 126.4, 125.8, 125.0, 124.6, 115.4, 105.4, 103.9, 103.6, 78.4, 56.1, 56.0, 55.6, 39.4, 32.9, 20.5, 17.0 ppm. HRMS (ESI): calcd. for $C_{27}H_{36}NO_4$ $[M+H]^+$ 438.2639, found 438.2635. Filtering the insoluble solid out of the organic/aqueous phase during the workup procedure gave **5a** (34 mg, 12%) as an off-white solid. Other data were the same as those of racemic **5** and **5a** in procedure **A**.

Preparation of 1a From (+)-5. (+)-**5** (45 mg, 0.1 mmol, 62% ee) provided by above procedure (Table 1, entry 4) was dissolved in ethanol (2 mL), conc.HCl (0.5 mL, 36–38%) and formaldehyde solution (0.5 mL, 37%) was then added, the reaction mixture was heated at reflux for 12 h under an atmosphere of Ar. After removing most of ethanol, aqueous NaOH (1.0 M, 10 mL) was added and the mixture was extracted with CH_2Cl_2 (3 × 10 mL), the combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. Purification of the residue by flash chromatography with 20/1 (v/v) CH_2Cl_2/CH_3OH gave **1a** (33 mg, 91%) as a white solid; m.p. 215–217 °C (ref.[2h] 209–211 °C). Chiral HPLC analysis (Chiralcel AD-H column, i-PrOH: hexane = 50:50, 1.0 mL/min) showed that the product had an enantiomeric excess of 60%. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.92 (s, 1 H, Ar-H), 7.91 (d, J = 2.4 Hz, 1 H, Ar-H), 7.83 (d, J = 9.2 Hz, 1 H, Ar-H), 7.32 (s, 1 H, Ar-H), 7.21 (dd, J = 9.2, 2.4 Hz, 1 H, Ar-H), 4.71 (d, J = 14.8 Hz, 1 H, 9-H), 4.11 (s, 3 H, OMe), 4.07 (s, 3 H, OMe), 4.02 (s, 3 H, OMe), 3.71 (d, J = 14.8 Hz, 1 H, 9-H), 3.44–3.50 (m, 1 H, 13a-H), 3.40–3.33 (m, 1 H, 14-H), 2.85–2.96 (m, 1 H, 14-H), 2.42–2.50 (m, 2 H, 11-H), 2.19–2.26 (m, 1 H, 13-H), 2.00–2.06 (m, 1 H, 13-H), 1.89–1.94 (m, 1 H, 12-H), 1.75–1.79 (m, 1 H, 12-H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.4, 149.4, 148.3, 130.2, 127.1, 126.8, 125.6,

124.3, 124.2, 123.5, 114.9, 104.7, 104.0, 103.8, 60.2, 56.0, 55.9, 55.5, 55.1, 53.9, 33.8, 31.3, 21.6 ppm.

Preparation of 7a/7b From 6. Lithiation of *N*-Boc-pyrrolidine according to procedure **B**, then a suspension of **6** (296 mg, 1.0 mmol) in Et_2O（10 mL） was added. Purification by flash chromatography with 1/4 (v/v) EtOAc/hexane gave the minor diastereomer **7a** (122 mg, 26%) as a white solid; m.p.195–197 °C. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.14 (s, 1 H, Ar-H), 7.88–7.75 (m, 4 H, Ar-H), 7.18 (dd, *J* = 8.8, 2.0 Hz, 1 H, Ar-H), 6.11 (s, 1 H, Ar-CH), 4.28–4.35 (m, 1 H, N-CH, 2-H), 4.18 (s, 3 H, OMe), 4.08 (s, 3 H, OMe), 4.01 (s, 3 H, OMe), 3.40–3.48 (m, 2 H, N-CH_2, 5-H), 2.43–2.47 (m, 1 H, 3-H), 2.07–2.15 (m, 1 H, 3-H), 1.93–2.02 (m, 1 H, 4-H), 1.64–1.72 (m, 1 H, 3-H), 1.53 (s, 9 H, CH_3) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.0, 155.5, 149.6, 148.5, 133.0, 130.6, 130.3, 125.7, 125.3, 124.3, 121.5, 115.2, 105.6, 103.8, 103.3, 79.4, 70.2, 61.6, 56.7, 55.9, 55.6, 48.1, 28.6, 25.0, 24.1 ppm; HRMS (ESI): calcd. for $C_{27}H_{33}NNaO_6$ $[M+Na]^+$ 490.2200, found 490.2197; and the major diastereomer **7b** (286 mg, 61%) as a white foamy solid; m.p. 93–95 °C; ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.97 (brs, 1 H, Ar-H), 7.90 (s, 1 H, Ar-H), 7.82 (s, 1 H, Ar-H), 7.75 (d, *J* = 8.8 Hz, 1 H, Ar-H), 7.63 (brs, 1 H, Ar-H), 7.17 (dd, *J* = 8.8, 2.0 Hz, 1 H, Ar-H), 6.21 (brs, 1 H, OH), 5.09 (brs, 1 H, Ar-CH), 4.63 (brs, 1 H, N-CH, 2-H), 4.10 (s, 3 H, OMe), 4.08 (s, 3 H, OMe), 3.99 (s, 3 H, OMe), 3.42–3.50 (m, 2 H, N-CH_2, 5-H), 1.79–1.91 (m, 1 H, 3-H), 1.66–1.76 (m, 1 H, 3-H), 1.54 (s, 9 H, CH_3), 1.37–1.47 (m, 2 H, 4-H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.6, 158.3, 149.0, 148.6, 133.0, 131.0, 130.3, 126.0, 125.6, 125.2, 115.5, 106.0, 103.7, 103.7, 80.9, 63.6, 56.0, 55.9, 55.5, 47.8, 29.0, 28.5, 24.1 ppm; HRMS (ESI): calcd. for $C_{27}H_{33}NNaO_6$ $[M+Na]^+$ 490.2200, found 490.2196.

Preparation of 2 From 7a. To a solution of **7a** (94 mg, 0.2 mmol) in ethanol (5 mL) was added conc.HCl (0.5 mL, 36–38%), the reaction mixture was heated at reflux for 1 h, then formaldehyde solution (2.0 mL, 37%) was added, the reaction mixture was heated at reflux for 56 h under an atmosphere of Ar. After removing most of ethanol, aqueous NaOH (1.0 M, 10 mL) was added and the mixture was extracted with CH_2Cl_2 (3 × 10 mL), the combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. Purification of the residue by flash chromatography with 20/1 (v/v) CH_2Cl_2/CH_3OH gave **2** (44 mg, 58%) as a light-yellow solid; m.p. 221–223 °C. $[\alpha]_D^{26}$ = +197.4 (c 0.23, $CHCl_3$); {ref.[12] m.p. 237–239 °C, $[\alpha]_D^{11}$ = –217.1 (c 0.23, $CHCl_3$)}; Chiral HPLC analysis (Phenomenex Lux Cellulose-1 column, i-PrOH:CH_3CN (0.1% Et_3N) = 5:95, 1.0 mL/min) showed that the product had an enantiomeric excess of 97%. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.86 (s, 1 H, Ar-H), 7.84 (s, 1 H, Ar-H), 7.72 (d, *J* = 2.0 Hz, 1 H, Ar-H), 7.03 (d, *J* = 9.2 Hz, 1 H, Ar-H), 6.85 (dd, J = 9.2, 2.0 Hz, 1 H, Ar-H), 4.94 (s, 1 H, 14-H), 4.79 (brs, 1 H, OH), 4.15 (s, 3 H, OMe), 4.11 (s, 3 H, OMe), 4.02 (s, 3 H, OMe), 3.55 (d, *J* = 15.6 Hz, 1 H, 9-H), 3.16–3.20 (d, *J* = 15.6 Hz, 1 H, 9-H), 3.13–3.16 (m, 1 H, 11-H), 2.35–2.42 (m, 2 H, 13a-H, 12-H), 2.17–2.25 (m, 1 H, 11-H), 2.07–1.95 (m, 1 H, 12-H), 1.95–1.85 (m, 2 H, 13-H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.7, 149.4, 148.3, 130.5, 127.7, 127.2, 126.8, 124.2, 123.7, 122.8, 114.6, 105.2, 104.0, 103.3, 65.4, 64.8, 56.1, 55.9, 55.4, 55.3, 53.4, 24.0, 21.6 ppm.

Preparation of 2 From 7b. To a solution of compound **7b** (219 mg, 0.47 mmol) in ethanol (12 mL) was added conc.HCl (1.0 mL, 36–38%), the reaction mixture was heated at reflux for 1 h, then formaldehyde solution (4.0 mL, 37%) was added, the reaction mixture was heated at reflux for 60 h under an atmosphere of Ar. Workup was similar to above procedure, purification by flash chromatography gave **2** (95 mg, 54%) as a light-yellow solid. $[\alpha]_D^{26}$ = +191.6 (c 0.23, $CHCl_3$); Chiral HPLC analysis (Phenomenex Lux Cellulose-1 column, i-PrOH:CH_3CN (0.1% Et_3N) = 5:95, 1.0 mL/min) showed that the product had an enantiomeric excess of 96%. Other data were the same as above.

Preparation of 1a From 2. Two parts of **2** (44 + 95 mg, 0.367 mmol) prepared from **7a** and **7b** were gathered and dissolved in trifluoroacetic acid (4 mL), then triethylsilane (0.36 g, 3.1 mmol) was added, and the resulting mixture was stirred at room temperature for 12 h in the dark. The solvent was made basic with aqueous NaOH (2.0 M, 40 mL) and extracted with CH_2Cl_2 (3 × 20 mL), the combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. Purification of the residue by a flash chromatography using basic alumina (200−300 mesh) with 40/1 (v/v) CH_2Cl_2/CH_3OH gave **1a** (127 mg, 96%) as a white solid. Chiral HPLC analysis (Chiralcel AD-H column, i-PrOH: hexane = 50:50, 1.0 mL/min) showed that the product had an enantiomeric excess of 98%. $[\alpha]_D^{25}$ = +80.9 (c 0.45, $CHCl_3$); {ref.[2h] $[\alpha]_D^{20}$ = +85 (c 2.0, $CHCl_3$); 99% ee}; other data were the same as those of **1a** prepared from **5**.

Supporting Information

^{1}H and ^{13}C NMR spectroscopic data for **5**, **5a**, **4c**, **7a**, **7b**, **1a**, and **2**. HRMS (ESI) data for **5a**, **4c**, **7a**, **7b**, and **2**. Chiral-HPLC chromatogram for **5**, **2**, **1a**.

Acknowledgments

This work was supported by the National Key Project for Basic Research (2010CB126106), the National Natural Science Foundation of

China (21132003, 21121002, 21372131, 21002053), Tianjin Natural Science Foundation (11JCZDJC20500), and the Specialized Research Fund for the Doctoral Program of Higher Education (20130031110017).

References

1 a) A. N. Ratnagiriswaran, K. Venkatachalam, *Indian J. Med. Res.***1935**, *22*, 433–441; b) E. Gellert, *J. Nat. Prod.* **1982**, *45*, 50–73; c) Z. G. Li, Z. Jin, R. Q. Huang, *Synthesis* **2001**, *16*, 2365–2378; d) J. P. Michael, *Nat. Prod. Rep.* **2001**, 18, 520–542; e) D. S. Bhakuni, *J. Indian Chem. Soc.* **2002**, *79*, 203–210; f) J. P. Michael, *Nat. Prod. Rep.* **2005**, *22*, 603–626; g) A. G. Damu, P. K. Kuo, L. S. Shi, C. Y. Li, C. S. Kuoh, P. L. Wu, T. S. Wu, *J. Nat. Prod.* **2005**, *68*, 1071–1075; h) A. Toribio, A. Bonfils, E. Delannay, E. Prost, D. Harakat, E. Henon, B. Richard, M. Litaudon, J. M. Nuzillard, J. H. Renault, *Org. Lett.* **2006**, *8*, 3825–3828; i) S. R. Chemler, *Curr. Bioact. Compd.* **2009**, *5*, 2–19; j) H. Y. Min, H. J. Chung, E. H. Kim, S. Kim, E. J. Park, S. K. Lee, *Biochem. Pharmacol.* **2010**, *80*, 1356–1364; k) C. W. Yang, Z. Y. Lee, I. J. Kang, D. L. Barnard, J. T. Jan, D. Lin, C. W. Huang, T. K. Yeh, Y. S. Chao, S. J. Lee, *Antiviral Res.* **2010**, *88*, 160–168.

2 For recent selected examples, see: a) S. Kim, J. Lee, T. Lee, H. G. Park, D. Kim, *Org. Lett.* **2003**, *5*, 2703–2706; b) A. Fürstner, J. W. Kennedy, *Chem. Eur. J.* **2006**, *12*, 7398–7410; c) W. Zeng, S. R. Chemler, *J. Org. Chem.* **2008**, *73*, 6045–6047; d) X. M. Yang, Q. Shi, K. F. Bastow, K. H. Lee, *Org. Lett.* **2010**, *12*, 1416–1419; e) A. Stoye, T. Opatz, *Org. Lett.* **2010**, *12*, 2140–2141; f) D. N. Mai, J. P. Wolfe, *J. Am. Chem. Soc.* **2010**, *132*, 12157–12159; g) M. B. Cui, H. J. Song, A. Z. Feng, Z. W. Wang, Q. M. Wang. *J. Org. Chem.* **2010**, *75*, 7018–7021; h) Z. W. Wang, Z. Li, K. L. Wang, Q. M. Wang, *Eur. J. Org. Chem.* **2010**, 292–299; i) B. Su, C. L. Cai, Q. M. Wang, *J. Org. Chem.* **2012,** *77*, 7981–7987; j) B. Su, F. Z. Chen, Q. M. Wang, *J. Org. Chem.* **2013,** *78*, 2775–2779; k) W. J. Ying, J. W. Herndon, *Eur. J. Org. Chem.* **2013**, 3112–3122.

3 a) M. Ihara, Y. Takino, M. Tomotake, K. Fukumoto, *J. Chem. Soc. Perkin Trans 1*, **1990**, *8*, 2287–2292; b) D. L. Comins, X. Chen, L. A. Morgan, *J. Org. Chem.* **1997**, *62*, 7435–7438; c) H. Suzuki, S. Aoyagi, C. Kibayashi, *J. Org. Chem.* **1995**, *60*, 6114–6122; d) D. David, L. Stéphane, C. Axel, D. Eric, G. Pierre, *Eur. J. Org. Chem.* **2010**, 1943–1950.

4 a) S. T. Kerrick, P. Beak, *J. Am. Chem. Soc.* **1991**, *113* , 9708–9710; b) P. Beak, S. T. Kerrick, S. D. Wu, J. X. Chu, *J. Am. Chem. Soc.* **1994**, *116*, 3231–3239; c) D. Hoppe, F. Hintze, P. Tebben, *Angew. Chem. Int. Ed.* **1990**, *29*, 1424–1425; d) R. K. Dieter, C. M. Topping, K. R. Chandupatla, K. Lu, *J. Am. Chem. Soc.* **2001**, *123*, 5132–5133; e) K. R. Campos, A. Klapars, J. H. Waldman, P. G. Dormer, C. Y. Chen, *J. Am. Chem. Soc.* **2006**, *128*, 3538–3539.

5 For reviews, see: a) P. Beak, A. Basu, D. J. Gallagher, Y. S. Park, S. Thayumanavan, *Acc. Chem. Res.* **1996**, *29*, 552–560; b) D. Hoppe, T. Hense, *Angew. Chem. Int. Ed.* **1997**, *36*, 2282–2316.

6 For examples: a) R. T. Watson, V. K. Gore, K. R. Chandupatla, R. K. Dieter, J. P. Snyder, *J. Org. Chem.* **2004**, *69*, 6105–6114; b) R. K. Dieter, N. Y. Chen, *J. Org. Chem.* **2006**, *71*, 5674–5678; c) D. Stead, P. O'Brien, A. Sanderson, *Org. Lett.* **2008**, *10*, 1409–1412 ; d) A. Klapars, K. R. Campos, J. H. Waldman, D. Zewge, P. G. Dormer, C. Y. Chen, *J. Org. Chem.* **2008**, *73*, 4986–4993; e) J. L. Bilke, S. P. Moore, P. O'Brien, J. Gilday, *Org. Lett.* **2009**, *11*, 1935–1938 ; for an unsuccessful trial about alkylation of *N*-Boc-pyrrolidine, see: h) S. Yamashita, N. Kurono, H. Senboku, M. Tokuda, K. Orito, *Eur. J. Org. Chem.* **2009**, 1173–1180.

7 For the preparation of **4a**, see: a) T. R. Govindachari, I. S. Ragade, N. Viswanatha, *J. Chem. Soc.* **1962**, 1357–1360; for **6**: b) M. L. Bremmer, N. A. Khatri, S. M. Weinreb, *J. Org. Chem.* **1983**, *48*, 3661–3666.

8 K. L. Wang, M. Y. Lü, Q. M. Wang, R. Q. Huang, *Tetrahedron* **2008**, *64*, 7504–7510.

9 a) W. F. Bailey, J. J. Patricia, *J. Organomet. Chem.* **1988**, *352*, 1–46; b) D. Seyferth, *Organometallics* **2006**, *25*, 2–24.

10 a) W. K. Robbins, R. H. Eastman, *J. Am. Chem. Soc.* **1970**, *92* , 6077–6079; b) V. W. Bowry, K. U. Ingold, *J. Am. Chem. Soc.* **1992**, *114*, 4992-4996; c) M. J. Fernández, L. Gude and A. Lorente, *Tetrahedron Lett.* **2001**, *42*, 891–893.

11 P. Beak, D. J. Allen, *J. Am. Chem. Soc.* **1992**, *114*, 3420-3425, and references cited therein.

12 Z. Rui, S. D. Fang, Y. Chen, S. X. Lü, *Zhiwu Xuebao* **1991**, *33*, 870–875.

Total Synthesis of Phenanthroindolizidine Alkaloids via Asymmetric Deprotonation of *N*-Boc-pyrrolidine



A concise synthesis of two typical phenanthroindolizidine alkaloids via an asymmetric deprotonation/ diastereoselective carbonyl addition stragety is described.